Business Segments · Payments for Restructuring
Oncology & Multispecialty — Payments for Restructuring
Year-over-year, this metric declined by 100.0%, from $500.00K to $0.00. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ2 2024
Last reportedQ1 2026
How to read this metric
High payments indicate active execution of restructuring plans, which should ideally lead to future cost savings.
Detailed definition
The actual cash outflow associated with executing restructuring plans, such as severance payments or lease termination f...
Peer comparison
Standard cash flow disclosure for restructuring activities.
Metric ID:
mck_segment_oncology_multispecialty_payments_for_restructuringHistorical Data
2 years
| FY'25 | FY'26 | |
|---|---|---|
| Value | $2.00M | $0.00 |
| YoY Change | — | -100.0% |
Range$0.00 – $2.00M
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's oncology & multispecialty — payments for restructuring?
- McKesson (MCK) reported oncology & multispecialty — payments for restructuring of $0.00 in Q1 2026.
- How has McKesson's oncology & multispecialty — payments for restructuring changed year-over-year?
- McKesson's oncology & multispecialty — payments for restructuring decreased by 100.0% year-over-year, from $500.00K to $0.00.
- What does oncology & multispecialty — payments for restructuring mean?
- Actual cash spent on restructuring activities.